Lansoprazole

Generic Name
Lansoprazole
Brand Names
Prevacid, Prevpac
Drug Type
Small Molecule
Chemical Formula
C16H14F3N3O2S
CAS Number
103577-45-3
Unique Ingredient Identifier
0K5C5T2QPG
Background

Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.

Indication

Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis. Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy).

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
Associated Therapies
-

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2008-03-18
Last Posted Date
2017-01-23
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
9
Registration Number
NCT00637416
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2007-10-18
Last Posted Date
2018-06-01
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
16
Registration Number
NCT00546117
Locations
🇺🇸

St. Louis Children's Hospital, Saint Louis, Missouri, United States

The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain

First Posted Date
2007-05-11
Last Posted Date
2021-12-06
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
2
Registration Number
NCT00472186
Locations
🇺🇸

Childrens Hospital Boston, Boston, Massachusetts, United States

🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-05-09
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
831
Registration Number
NCT00471094

Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis

Phase 1
Completed
Conditions
First Posted Date
2007-04-11
Last Posted Date
2011-01-11
Lead Sponsor
Arkansas Children's Hospital Research Institute
Target Recruit Count
18
Registration Number
NCT00458614
Locations
🇺🇸

Arkansas Children's Hospital Little Rock, Little Rock, Arkansas, United States

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

First Posted Date
2007-03-07
Last Posted Date
2017-03-29
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
38
Registration Number
NCT00444145
Locations
🇺🇸

Vanderbilt University Medical Center, Endoscopy Lab, TVC 1410, Nashville, Tennessee, United States

Lansoprazole to Treat Children With Asthma

Phase 4
Completed
Conditions
Interventions
First Posted Date
2007-03-01
Last Posted Date
2012-12-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
306
Registration Number
NCT00442013
Locations
🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

and more 17 locations

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Phase 3
Completed
Conditions
First Posted Date
2006-10-19
Last Posted Date
2010-05-25
Lead Sponsor
Novartis
Target Recruit Count
576
Registration Number
NCT00390390
Locations
🇺🇸

Palm Beach Research, West Palm Beach, Florida, United States

🇺🇸

Medical Edge Healthcare Group, Dallas, Texas, United States

🇺🇸

Gaslamp Medical Center, San Diego, California, United States

and more 25 locations

Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux

First Posted Date
2006-08-29
Last Posted Date
2012-08-24
Lead Sponsor
American Institute for Voice and Ear Research
Target Recruit Count
18
Registration Number
NCT00369265
Locations
🇺🇸

Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States

🇺🇸

American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States

🇺🇸

Cornell University, Van Lawrence Voice Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath